To move the field forward and to expedite the pathway from discovery to regulatory approval, a workshop with key stakeholders was held in September 2016 to develop a consensus on treatment endpoints to guide the design of clinical trials aimed at hepatitis B cure. The consensus reached was that...
Following FDA approval, GigaGen's therapy enters Phase 1 clinical trials as the first recombinant human polyclonal therapy for hepatitis B. Since Contagion's first interview last year with Carter Keller, senior VP at Grifols and head of GigaGen, there has been significant progress i...
Optimal treatment regimes, such as the most effective treatment start times for the reduction of viral load, have been identified. Our analysis highlights the potential benefit of antibody therapies currently in clinical trials, and allows modelling of the impacts of DAAs under development....
Demonstrated safety profile in clinical trials of more than 10,000 participants9 §Compared to those who received 3 doses of Engerix‑B.5,9 *As of April 2022, the ACIP recommends hepatitis B vaccination for all adults aged 19–59 and for adults aged ≥60 years with risk factors. Adults...
ANRS Research Centre in France is running IP-CURE-B proof of concept (PoC) Phase II clinical trial (NCT05045261), which is due to end on 30 June 2024. The aim of the study is to evaluate whether stopping nucleotide or nucleoside analogue (NUC) after selgantolimod (SLGN) treatment can...
Treatment of chronic hepatitis B with pattern recognition receptor agonists: Current status and potential for a cure JinhongChang,Ju-TaoGuo, inAntiviral Research, 2015 Abstract Hepatitis B virus(HBV) has been considered to be a “stealth virus” that induces negligible innate immune responses during...
Chronic hepatitis B (CHB) is currently treated with IFN-α and nucleos(t)ide analogues, which have many clinical benefits, but there is no ultimate cure. The major problem consists in the persistence of cccDNA in infected hepatocytes. Because no antiviral drug has been evaluated which significa...
Clinical cure (or functional cure):6,112,114–116 HBsAg remains negative (with or without the presence of anti-HBs), HBV DNA is undetectable, and liver biochemical indicators are normal following withdrawal of the treatment. However, because cccDNA remains in the nuclei of liver cells, patients...
73763989, JNJ-64300535, and nucleos(t)ide analogs in virologically suppressed, hepatitis B e antigen (HBeAg)-negative participants with chronic hepatitis B virus infection (OSPREY). ClinicalTrials.gov. Updated March 16, 2022. Accessed April 8, 2022. https://clinicaltrials.gov/ct2/show/NCT...
immune responses over other types of vaccines, and are also endowed with strong intrinsic adjuvant property to activate innate immune compartment7. Several mRNA-based prophylactic or therapeutic vaccines for infections, malignancies or other diseases are currently being evaluated in clinical trials8,...